Literature DB >> 25929371

Independent and combined influence of the FTO rs9939609 and MC4Rrs17782313 polymorphisms on hypocaloric diet induced changes in body mass and composition and energy metabolism in non-morbid obese premenopausal women.

Idoia Labayen1, Javier Margareto2, Sara Maldonado-Martin3, Ilargi Gorostegi3, Maitane Illera1, María Medrano1, Lurdes Barrenechea4, Eider Larrarte2.   

Abstract

PURPOSE: To examine the independent and combined influence of the FTOrs9939609 and the MC4Rrs17782313 polymorphisms on changes in fat mass (FM), resting energy expenditure (REE), leptin, and thyrotropin (TSH) levels, after a 12-week energy-restricted diet intervention in non-morbid premenopausal obese women.
METHODS: Fat mass (dual X-ray absorptiometry), REE (indirect calorimetry) and plasma leptin and thyrotropin levels were measured (before and after the intervention) in 77 obese (BMI: 33.9 ± 2.8 kg/m(2)) women (age: 36.8 ± 7.0y).
RESULTS: There were no significant differences across FTOrs9939609 genotype groups (TT vs. A allele carriers, Ps>0.1) on changes in body mass (-8.6 ± 3.2% vs. -8.7 ± 3.3 %), FM (12.8 ± 4.7% vs. -12.9 ± 6.3%), REE (-11.3 ± 4.7 vs. -9.4 ± 8.1%), leptin (-34.1 ± 25.1% vs. -43.5 ± 24.1%) or TSH (5.2 ± 34.5% vs. -1.7 ± 27.1%) levels. Moreover, it was not observed any significant difference on changes in body mass (-8.6 ± 3.6% vs. -8.9 ± 2.6%), FM (-12.7 ± 6.1% vs. -13.4 ± 5.3%), REE (-9.8 ± 7.4% -9.4 ± 9.4%), leptin (-39.0 ± 26.9% vs. -44.8 ± 18.4%) or TSH (-1.0 ± 30.0% vs. 1.5 ± 26.5%) levels between non-C allele carriers and C allele carriers of the MC4Rrs17782313 (Ps>0.3). Finally, there were no significant difference on changes in body mass and composition, REE, leptin or TSH levels among non-risk allele carriers, carriers of the C allele risk of the MC4Rrs17782313, carriers of the A allele of the FTOrs9939609 and carriers of both risk alleles after the 12-week energy-restricted diet intervention (Ps>0.1).
CONCLUSION: Carrying the A risk allele of the FTOrs9939609 and/or the C risk allele of the MC4Rrs17782313 did not influence body mass and FM loss, or REE decrease in obese women after a 12-week energy-restricted diet intervention. Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25929371     DOI: 10.3305/nh.2015.31.5.8666

Source DB:  PubMed          Journal:  Nutr Hosp        ISSN: 0212-1611            Impact factor:   1.057


  4 in total

1.  Association between the FTO rs9939609 single nucleotide polymorphism and dietary adherence during a 2-year caloric restriction intervention: Exploratory analyses from CALERIE™ phase 2.

Authors:  James L Dorling; Daniel W Belsky; Susan B Racette; Sai Krupa Das; Eric Ravussin; Leanne M Redman; Christoph Höchsmann; Kim M Huffman; William E Kraus; Michael S Kobor; Julia L MacIsaac; David T S Lin; David L Corcoran; Corby K Martin
Journal:  Exp Gerontol       Date:  2021-09-20       Impact factor: 4.032

2.  GOS Ameliorates Nonalcoholic Fatty Liver Disease Induced by High Fat and High Sugar Diet through Lipid Metabolism and Intestinal Microbes.

Authors:  Shuting Qiu; Jiajia Chen; Yan Bai; Jincan He; Hua Cao; Qishi Che; Jiao Guo; Zhengquan Su
Journal:  Nutrients       Date:  2022-07-01       Impact factor: 6.706

3.  Influence of FTO rs9939609 polymorphism on appetite, ghrelin, leptin, IL6, TNFα levels, and food intake of women with morbid obesity.

Authors:  Fernanda Cristina Carvalho Mattos Magno; Helena Chrispim Guaraná; Ana Carolina Proença Fonseca; Giselda Maria Kalil Cabello; João Régis Ivar Carneiro; Aline Pereira Pedrosa; Ana Carolina Ximenes; Eliane Lopes Rosado
Journal:  Diabetes Metab Syndr Obes       Date:  2018-05-14       Impact factor: 3.168

4.  Genetic test for the prescription of diets in support of physical activity.

Authors:  Zakira Naureen; Giacinto Abele Donato Miggiano; Barbara Aquilanti; Valeria Velluti; Giuseppina Matera; Lucilla Gagliardi; Alessandra Zulian; Roberta Romanelli; Matteo Bertelli
Journal:  Acta Biomed       Date:  2020-11-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.